;PMID: 9365186 ;source_file_1782.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..52] = [t:0..52] ;1)sentence:[e:58..149] = [t:58..149] ;2)section:[e:153..222] = [t:153..222] ;3)section:[e:226..327] = [t:226..327] ;4)sentence:[e:331..718] = [t:331..718] ;5)sentence:[e:720..866] = [t:720..866] ;6)sentence:[e:867..1003] = [t:867..1003] ;7)sentence:[e:1004..1229] = [t:1004..1229] ;8)sentence:[e:1230..1375] = [t:1230..1375] ;9)sentence:[e:1376..1619] = [t:1376..1619] ;10)sentence:[e:1620..1755] = [t:1620..1755] ;11)sentence:[e:1756..1926] = [t:1756..1926] ;12)sentence:[e:1927..2104] = [t:1927..2104] ;13)section:[e:2108..2152] = [t:2108..2152] ;section 0 Span:0..52 ;J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):157-66. (SEC (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem) (NNP:[18..21] Mol) (NNP:[22..26] Biol) (IN:[26..27] .) (CD:[28..32] 1997) (.:[33..39] Apr;61) (-LRB-:[39..40] -LRB-) (JJ:[40..42] 3-) (CD:[42..43] 6) (-RRB-:[43..44] -RRB-) (CD:[44..48] :157) (::[48..49] -) (CD:[49..51] 66) (.:[51..52] .))) ;sentence 1 Span:58..149 ;Effect of estrogen deprivation on the reproductive physiology of male and ;female primates. ;[68..76]:substance:"estrogen" (SENT (NP-HLN (NP (NN:[58..64] Effect)) (PP (IN:[65..67] of) (NP (NN:[68..76] estrogen) (NN:[77..88] deprivation))) (PP (IN:[89..91] on) (NP (NP (DT:[92..95] the) (JJ:[96..108] reproductive) (NN:[109..119] physiology)) (PP (IN:[120..122] of) (NP (NP (JJ:[123..127] male) (NML-1 (-NONE-:[127..127] *P*))) (CC:[128..131] and) (NP (JJ:[132..138] female) (NML-1 (NNS:[140..148] primates))))))) (.:[148..149] .))) ;section 2 Span:153..222 ;Shetty G, Krishnamurthy H, Krishnamurthy HN, Bhatnagar S, Moudgal RN. (SEC (FRAG (NNP:[153..159] Shetty) (NNP:[160..161] G) (,:[161..162] ,) (NNP:[163..176] Krishnamurthy) (NNP:[177..179] H,) (NNP:[180..193] Krishnamurthy) (NNP:[194..196] HN) (,:[196..197] ,) (NNP:[198..207] Bhatnagar) (NNP:[208..209] S) (,:[209..210] ,) (NNP:[211..218] Moudgal) (NNP:[219..221] RN) (.:[221..222] .))) ;section 3 Span:226..327 ;Center for Reproductive Biology and Molecular Endocrinology, Indian Institute ;of Science, Bangalore. (SEC (FRAG (NNP:[226..232] Center) (IN:[233..236] for) (NNP:[237..249] Reproductive) (NNP:[250..257] Biology) (CC:[258..261] and) (NNP:[262..271] Molecular) (NNP:[272..285] Endocrinology) (,:[285..286] ,) (NNP:[287..293] Indian) (NNP:[294..303] Institute) (IN:[304..306] of) (NNP:[308..315] Science) (,:[315..316] ,) (NNP:[317..326] Bangalore) (.:[326..327] .))) ;sentence 4 Span:331..718 ;The availability of CGS 16949A, CGS 20267 and CGP 47645, a series of ;aromatase inhibitors (AIs) having high specific activity and specificity, ;made possible this study wherein the need for estrogen (E) for regulating ;(a) follicular maturation/ovulation, luteal function and pregnancy ;establishment, and (b) testicular function of the bonnet monkey (Macaca ;radiata) has been examined. ;[351..361]:substance:"CGS 16949A" ;[363..372]:substance:"CGS 20267" ;[377..386]:substance:"CGP 47645" ;[400..421]:substance:"aromatase inhibitors" ;[423..426]:substance:"AIs" ;[522..530]:substance:"estrogen" ;[532..533]:substance:"E" (SENT (S (NP-SBJ (NP (DT:[331..334] The) (NN:[335..347] availability)) (PP (IN:[348..350] of) (NP (NP (NP (NN:[351..354] CGS) (NN:[355..361] 16949A)) (,:[361..362] ,) (NP (NN:[363..366] CGS) (CD:[367..372] 20267)) (CC:[373..376] and) (NP (NN:[377..380] CGP) (CD:[381..386] 47645))) (,:[386..387] ,) (NP (NP (DT:[388..389] a) (NN:[390..396] series)) (PP (IN:[397..399] of) (NP (NP (NP (NN:[400..409] aromatase) (NNS:[411..421] inhibitors)) (NP (-LRB-:[422..423] -LRB-) (NNS:[423..426] AIs) (-RRB-:[426..427] -RRB-))) (VP (VBG:[428..434] having) (NP (NP (ADJP-1 (JJ:[435..439] high)) (JJ:[440..448] specific) (NN:[449..457] activity)) (CC:[458..461] and) (NP (ADJP-1 (-NONE-:[461..461] *P*)) (NN:[462..473] specificity)))))))))) (,:[473..474] ,) (VP (VBD:[475..479] made) (S (NP-SBJ-3 (-NONE-:[479..479] *ICH*)) (ADJP-PRD (JJ:[480..488] possible)) (NP-3 (NP (DT:[490..494] this) (NN:[495..500] study)) (SBAR (WHPP (IN:[501..508] wherein)) (S (NP-SBJ-2 (NP (DT:[509..512] the) (NN:[513..517] need)) (PP (IN:[518..521] for) (NP (NP (NN:[522..530] estrogen)) (NP (-LRB-:[531..532] -LRB-) (NN:[532..533] E) (-RRB-:[533..534] -RRB-)))) (PP (IN:[535..538] for) (S-NOM (NP-SBJ (-NONE-:[538..538] *)) (VP (VBG:[539..549] regulating) (NP (NP (LST (LS:[550..553] -LRB-a-RRB-)) (NP (NP (JJ:[554..564] follicular) (NN:[566..576] maturation)) (SYM:[576..577] /) (NP (NN:[577..586] ovulation))) (,:[586..587] ,) (NP (JJ:[588..594] luteal) (NN:[595..603] function)) (CC:[604..607] and) (NP (NN:[608..617] pregnancy) (NN:[618..631] establishment))) (,:[631..632] ,) (CC:[633..636] and) (NP (LST (LS:[637..640] -LRB-b-RRB-)) (NP (NP (JJ:[642..652] testicular) (NN:[653..661] function)) (PP (IN:[662..664] of) (NP (NP (DT:[665..668] the) (NN:[669..675] bonnet) (NN:[676..682] monkey)) (NP (-LRB-:[683..684] -LRB-) (NNP:[684..690] Macaca) (NNP:[691..698] radiata) (-RRB-:[698..699] -RRB-))))))))))) (VP (VBZ:[700..703] has) (VP (VBN:[704..708] been) (VP (VBN:[709..717] examined) (NP-2 (-NONE-:[717..717] *)))))))))) (.:[717..718] .))) ;sentence 5 Span:720..866 ;Generally these compounds, used in the range of 500 microg to 2.5 mg/day did ;not inhibit follicular maturation although they did reduce E levels. ;[736..745]:substance:"compounds" ;[768..771]:quantitative-value:"500" ;[772..778]:quantitative-units:"microg" ;[782..785]:quantitative-value:"2.5" ;[786..792]:quantitative-units:"mg/day" ;[857..858]:substance:"E" (SENT (S (ADVP (RB:[720..729] Generally)) (NP-SBJ (NP (DT:[730..735] these) (NNS:[736..745] compounds)) (,:[745..746] ,) (VP (VBN:[747..751] used) (NP (-NONE-:[751..751] *)) (PP (IN:[752..754] in) (NP (NP (DT:[755..758] the) (NN:[759..764] range)) (PP (IN:[765..767] of) (NP (NP (QP (CD:[768..771] 500) (NN:[772..778] microg) (TO:[779..781] to) (CD:[782..785] 2.5)) (NN:[786..788] mg)) (PP (SYM:[788..789] /) (NP (NN:[789..792] day))))))))) (VP (VBD:[793..796] did) (RB:[797..800] not) (VP (VB:[802..809] inhibit) (NP (JJ:[810..820] follicular) (NN:[821..831] maturation)) (SBAR-ADV (IN:[832..840] although) (S (NP-SBJ (PRP:[841..845] they)) (VP (VBD:[846..849] did) (VP (VB:[850..856] reduce) (NP (NN:[857..858] E) (NNS:[859..865] levels)))))))) (.:[865..866] .))) ;sentence 6 Span:867..1003 ;Although low doses had no effect on ovulation it appears that relatively ;high doses of CGS 20267 and CGP 47645 could be inhibiting it. ;[955..965]:substance:"CGS 20267" ;[970..979]:substance:"CGP 47645" (SENT (S (SBAR-ADV (IN:[867..875] Although) (S (NP-SBJ (JJ:[876..879] low) (NNS:[881..886] doses)) (VP (VBD:[887..890] had) (NP (NP (DT:[891..893] no) (NN:[894..900] effect)) (PP (IN:[901..903] on) (NP (NN:[904..913] ovulation))))))) (NP-SBJ (PRP:[914..916] it)) (VP (VBZ:[917..924] appears) (SBAR (IN:[925..929] that) (S (NP-SBJ (NP (ADJP (RB:[930..940] relatively) (JJ:[941..945] high)) (NNS:[946..951] doses)) (PP (IN:[952..954] of) (NP (NP (NN:[955..958] CGS) (CD:[960..965] 20267)) (CC:[966..969] and) (NP (NN:[970..973] CGP) (CD:[974..979] 47645))))) (VP (MD:[980..985] could) (VP (VB:[986..988] be) (VP (VBG:[989..999] inhibiting) (NP (PRP:[1000..1002] it)))))))) (.:[1002..1003] .))) ;sentence 7 Span:1004..1229 ;Three oral doses of letrozole (CGS 20267, each dose of 2 mg) during the ;follicular phase resulted in the formation of multiple follicles in cycling ;females, and these could be ovulated by exogenous hCG (1000 IU) treatment. ;[1024..1033]:substance:"letrozole" ;[1035..1045]:substance:"CGS 20267" ;[1060..1061]:quantitative-value:"2" ;[1062..1064]:quantitative-units:"mg" ;[1205..1208]:substance:"hCG" ;[1210..1214]:quantitative-value:"1000" ;[1215..1217]:quantitative-units:"IU" (SENT (S (S (NP-SBJ (NP (CD:[1004..1009] Three) (JJ:[1010..1014] oral) (NNS:[1015..1020] doses)) (PP (IN:[1021..1023] of) (NP (NN:[1024..1033] letrozole))) (PRN (-LRB-:[1034..1035] -LRB-) (FRAG (NP (NN:[1035..1038] CGS) (CD:[1040..1045] 20267)) (,:[1045..1046] ,) (NP (NP (DT:[1047..1051] each) (NN:[1052..1056] dose)) (PP (IN:[1057..1059] of) (NP (CD:[1060..1061] 2) (NN:[1062..1064] mg))))) (-RRB-:[1064..1065] -RRB-)) (PP-TMP (IN:[1066..1072] during) (NP (DT:[1073..1076] the) (JJ:[1077..1087] follicular) (NN:[1088..1093] phase)))) (VP (VBD:[1094..1102] resulted) (PP-CLR (IN:[1103..1105] in) (NP (NP (DT:[1106..1109] the) (NN:[1110..1119] formation)) (PP (IN:[1121..1123] of) (NP (JJ:[1124..1132] multiple) (NNS:[1133..1142] follicles))))) (PP-LOC (IN:[1143..1145] in) (NP (VBG:[1146..1153] cycling) (NNS:[1154..1161] females))))) (,:[1161..1162] ,) (CC:[1163..1166] and) (S (NP-SBJ-1 (DT:[1167..1172] these)) (VP (MD:[1173..1178] could) (VP (VB:[1179..1181] be) (VP (VBN:[1182..1190] ovulated) (NP-1 (-NONE-:[1190..1190] *)) (PP-MNR (IN:[1191..1193] by) (NP (JJ:[1195..1204] exogenous) (NN:[1205..1208] hCG) (PRN (-LRB-:[1209..1210] -LRB-) (NP (CD:[1210..1214] 1000) (NN:[1215..1217] IU)) (-RRB-:[1217..1218] -RRB-)) (NN:[1219..1228] treatment))))))) (.:[1228..1229] .))) ;sentence 8 Span:1230..1375 ;Although administration of AI during the early luteal phase had no effect on ;progesterone (P) production, it prevented pregnancy establishment. ;[1257..1259]:substance:"AI" ;[1308..1320]:substance:"progesterone" ;[1322..1323]:substance:"P" (SENT (S (SBAR-ADV (IN:[1230..1238] Although) (S (NP-SBJ (NP (NN:[1239..1253] administration)) (PP (IN:[1254..1256] of) (NP (NN:[1257..1259] AI))) (PP-TMP (IN:[1260..1266] during) (NP (DT:[1267..1270] the) (JJ:[1272..1277] early) (JJ:[1278..1284] luteal) (NN:[1285..1290] phase)))) (VP (VBD:[1291..1294] had) (NP (NP (DT:[1295..1297] no) (NN:[1298..1304] effect)) (PP (IN:[1305..1307] on) (NP (NML (NML (NN:[1308..1320] progesterone)) (NML (-LRB-:[1321..1322] -LRB-) (NN:[1322..1323] P) (-RRB-:[1323..1324] -RRB-))) (NN:[1325..1335] production))))))) (,:[1335..1336] ,) (NP-SBJ (PRP:[1337..1339] it)) (VP (VBD:[1340..1349] prevented) (NP (NN:[1351..1360] pregnancy) (NN:[1361..1374] establishment))) (.:[1374..1375] .))) ;sentence 9 Span:1376..1619 ;Whereas AI administration in the female had no significant effect on ;luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels ;(except at high drug dosages), it significantly increased serum testosterone ;(T) levels in the male. ;[1384..1386]:substance:"AI" ;[1446..1465]:substance:"luteinizing hormone" ;[1467..1469]:substance:"LH" ;[1475..1503]:substance:"follicle stimulating hormone" ;[1506..1509]:substance:"FSH" ;[1534..1538]:substance:"drug" ;[1583..1595]:substance:"testosterone" ;[1597..1598]:substance:"T" (SENT (S (SBAR-ADV (IN:[1376..1383] Whereas) (S (NP-SBJ (NP (NN:[1384..1386] AI) (NN:[1387..1401] administration)) (PP-LOC (IN:[1402..1404] in) (NP (DT:[1405..1408] the) (NN:[1409..1415] female)))) (VP (VBD:[1416..1419] had) (NP (NP (DT:[1420..1422] no) (JJ:[1424..1435] significant) (NN:[1436..1442] effect)) (PP (IN:[1443..1445] on) (NP (NP (NML (NML (VBG:[1446..1457] luteinizing) (NN:[1458..1465] hormone)) (NML (-LRB-:[1466..1467] -LRB-) (NN:[1467..1469] LH) (-RRB-:[1469..1470] -RRB-))) (NML-1 (-NONE-:[1470..1470] *P*))) (CC:[1471..1474] and) (NP (NML (NML (NN:[1475..1483] follicle) (VBG:[1484..1495] stimulating) (NN:[1496..1503] hormone)) (NML (-LRB-:[1505..1506] -LRB-) (NN:[1506..1509] FSH) (-RRB-:[1509..1510] -RRB-))) (NML-1 (NNS:[1511..1517] levels))))) (PRN (-LRB-:[1518..1519] -LRB-) (PP (IN:[1519..1525] except) (PP (IN:[1526..1528] at) (NP (JJ:[1529..1533] high) (NN:[1534..1538] drug) (NNS:[1539..1546] dosages)))) (-RRB-:[1546..1547] -RRB-)))))) (,:[1547..1548] ,) (NP-SBJ (PRP:[1549..1551] it)) (ADVP-MNR (RB:[1552..1565] significantly)) (VP (VBD:[1566..1575] increased) (NP (NN:[1576..1581] serum) (NML (NML (NN:[1583..1595] testosterone)) (NML (-LRB-:[1596..1597] -LRB-) (NN:[1597..1598] T) (-RRB-:[1598..1599] -RRB-))) (NNS:[1600..1606] levels)) (PP-LOC (IN:[1607..1609] in) (NP (DT:[1610..1613] the) (NN:[1614..1618] male)))) (.:[1618..1619] .))) ;sentence 10 Span:1620..1755 ;Sustained high levels of T (30-50 ng/ml) could be maintained for 100 days by ;administering 2.5 mg of CGP 47465 orally once in 5 days. ;[1645..1646]:substance:"T" ;[1648..1653]:quantitative-value:"30-50" ;[1654..1659]:quantitative-units:"ng/ml" ;[1686..1689]:quantitative-value:"100" ;[1690..1694]:quantitative-units:"days" ;[1712..1715]:quantitative-value:"2.5" ;[1716..1718]:quantitative-units:"mg" ;[1722..1731]:substance:"CGP 47465" ;[1748..1749]:quantitative-value:"5" ;[1750..1754]:quantitative-units:"days" (SENT (S (NP-SBJ-1 (NP (VBN:[1620..1629] Sustained) (JJ:[1630..1634] high) (NNS:[1635..1641] levels)) (PP (IN:[1642..1644] of) (NP (NN:[1645..1646] T))) (PP (-LRB-:[1647..1648] -LRB-) (NP (NP (QP (CD:[1648..1650] 30) (HYPH:[1650..1651] -) (CD:[1651..1653] 50)) (NN:[1654..1656] ng)) (PP (SYM:[1656..1657] /) (NP (NN:[1657..1659] ml)))) (-RRB-:[1659..1660] -RRB-))) (VP (MD:[1662..1667] could) (VP (VB:[1668..1670] be) (VP (VBN:[1671..1681] maintained) (NP-1 (-NONE-:[1681..1681] *)) (PP (IN:[1682..1685] for) (NP (CD:[1686..1689] 100) (NNS:[1690..1694] days))) (PP-MNR (IN:[1695..1697] by) (S-NOM (NP-SBJ (-NONE-:[1697..1697] *)) (VP (VBG:[1698..1711] administering) (NP (NP (CD:[1712..1715] 2.5) (NN:[1716..1718] mg)) (PP (IN:[1719..1721] of) (NP (NN:[1722..1725] CGP) (CD:[1726..1731] 47465)))) (ADVP-MNR (RB:[1732..1738] orally)) (ADVP-TMP (RB:[1740..1744] once) (PP (IN:[1745..1747] in) (NP (CD:[1748..1749] 5) (NNS:[1750..1754] days)))))))))) (.:[1754..1755] .))) ;sentence 11 Span:1756..1926 ;Blockade of E synthesis in the male led to the disruption of testicular germ ;cell transformation, which in turn resulted in a significant reduction in ;sperm production. ;[1768..1769]:substance:"E" (SENT (S (NP-SBJ (NP (NN:[1756..1764] Blockade)) (PP (IN:[1765..1767] of) (NP (NN:[1768..1769] E) (NN:[1770..1779] synthesis))) (PP-LOC (IN:[1780..1782] in) (NP (DT:[1783..1786] the) (NN:[1787..1791] male)))) (VP (VBD:[1792..1795] led) (PP-CLR (TO:[1796..1798] to) (NP (NP (NP (DT:[1799..1802] the) (NN:[1803..1813] disruption)) (PP (IN:[1814..1816] of) (NP (JJ:[1818..1828] testicular) (NML (NN:[1829..1833] germ) (NN:[1834..1838] cell)) (NN:[1839..1853] transformation)))) (,:[1853..1854] ,) (SBAR (WHNP-1 (WDT:[1855..1860] which)) (S (NP-SBJ-1 (-NONE-:[1860..1860] *T*)) (VP (ADVP (IN:[1861..1863] in) (NN:[1864..1868] turn)) (VBD:[1869..1877] resulted) (PP-CLR (IN:[1878..1880] in) (NP (NP (DT:[1881..1882] a) (JJ:[1883..1894] significant) (NN:[1896..1905] reduction)) (PP (IN:[1906..1908] in) (NP (NN:[1909..1914] sperm) (NN:[1915..1925] production))))))))))) (.:[1925..1926] .))) ;sentence 12 Span:1927..2104 ;These studies with aromatase inhibitors in the monkey suggest that these ;compounds have a potential for use as fertility regulating agents in both ;the male and female primate. ;[1946..1966]:substance:"aromatase inhibitors" ;[2001..2010]:substance:"compounds" ;[2061..2067]:substance:"agents" (SENT (S (NP-SBJ (NP (DT:[1927..1932] These) (NNS:[1933..1940] studies)) (PP (IN:[1941..1945] with) (NP (NN:[1946..1955] aromatase) (NNS:[1956..1966] inhibitors))) (PP-LOC (IN:[1967..1969] in) (NP (DT:[1970..1973] the) (NN:[1975..1981] monkey)))) (VP (VBP:[1982..1989] suggest) (SBAR (IN:[1990..1994] that) (S (NP-SBJ (DT:[1995..2000] these) (NNS:[2001..2010] compounds)) (VP (VBP:[2011..2015] have) (NP (NP (DT:[2016..2017] a) (NN:[2018..2027] potential)) (PP (IN:[2028..2031] for) (NP (NP (NN:[2032..2035] use)) (PP (IN:[2036..2038] as) (NP (ADJP (NN:[2039..2048] fertility) (VBG:[2050..2060] regulating)) (NNS:[2061..2067] agents))) (PP-LOC (IN:[2068..2070] in) (NP (CC:[2071..2075] both) (NP (DT:[2076..2079] the) (JJ:[2080..2084] male) (NML-1 (-NONE-:[2084..2084] *P*))) (CC:[2085..2088] and) (NP (JJ:[2089..2095] female) (NML-1 (NN:[2096..2103] primate)))))))))))) (.:[2103..2104] .))) ;section 13 Span:2108..2152 ;PMID: 9365186 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2108..2112] PMID) (::[2112..2113] :) (CD:[2114..2121] 9365186) (NN:[2122..2123] -LSB-) (NNP:[2123..2129] PubMed) (::[2130..2131] -) (NN:[2132..2139] indexed) (IN:[2140..2143] for) (NNP:[2144..2152] MEDLINE-RSB-)))